S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

BDTX Black Diamond Therapeutics Inc

2.14

-0.11 (-4.89%)

Last Updated: 06:36:32

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Black Diamond Therapeutics Charts.

Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Black Diamond Therapeutics Charts.

Black Diamond Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 6 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Friday 1 November 2024 (2 months ago) • GlobeNewswire Inc.

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Tuesday 8 October 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 23 September 2024 (4 months ago) • Edgar (US Regulatory)

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
Monday 23 September 2024 (4 months ago) • GlobeNewswire Inc.

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Monday 23 September 2024 (4 months ago) • GlobeNewswire Inc.

More Black Diamond Therapeutics Inc News Articles

INTESA SANPAOLO

L&G Cyber Security UCITS...

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions